Posts Tagged ‘announcement’
Firebrick Launches Nasodine in Singapore via Nasodine-sg.com
Firebrick Pharma Limited (ASX:FRE) is proud to announce that its product, Nasodine® Nasal Spray, is now available for sale in Singapore. Customers will be able to order the product through Firebrick’s new website dedicated to support Singapore sales: www.nasodine-sg.com In Singapore, Nasodine is classified as a topical antiseptic and does not require approval or licensing…
Nasodine Phase 2 COVID-19 Trial Results Published
The Company is now advanced in our plans to introduce Nasodine in at least one international market.
Firebrick Phase 3 Trial fully recruited with 500 subjects
Firebrick Pharma is pleased to announce that its Phase 3 trial of Nasodine® Nasal Spray in the treatment for the common cold has successfully completed recruitment, with 500 subjects enrolled. “Subject to availability of the complete efficacy data and timely completion of the statistical analysis, we expect to report headline results of the trial by…
Nasodine COVID-19 Trial Achieves Primary Endpoint
Highlights Firebrick Pharma Limited is pleased to announce that its Phase 2 trial of Nasodine® Nasal Spray in COVID-19 achieved its primary endpoint. The primary endpoint was the reduction in viral load of SARS-CoV-2 over 4 days, based on culturable virus from throat and nasal swabs. Nasodine treatment resulted in 100% reduction by day 4,…
Investor Update on Key Projects
We are pleased to provide the following update on the Company’s key projects, which will be provided verbally by the Executive Chairman at a General Meeting of Shareholders, today. Phase 3 clinical trial of Nasodine® Nasal Spray (Nasodine): This trial started in 2022 and is a pivotal trial of Nasodine as a treatment for the…
Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
Firebrick Pharma is pleased to provide an update on the progress of the confirmatory Phase 3 clinical trial of Nasodine® Nasal Spray as a treatment for the common cold. The study, which commenced in 2022, aims to recruit 196 subjects with early-stage colds who are confirmed by PCR to have a viral infection (other than…
Nasodine Patent Allowed in Canada
Highlights Firebrick Pharma Limited (ASX:FRE) is pleased to announce that its core patent covering Nasodine® Nasal Spray as a treatment and preventative for the common cold has now been allowed in Canada. Once this proceeds to grant, it will bring the number of countries where this patent has been granted to 28, now covering North…
Nasodine COVID-19 Trial Concludes Recruitment – Results in June 2023
Firebrick Pharma is pleased to announce that its Phase 2 COVID-19 trial of Nasodine® Nasal Spray has closed for recruitment.
Firebrick Pharma’s Phase 3 Trial of Nasodine Resumes
Two clinical sites in Australia are now open for recruitment and three sites in South Africa will be open in the next week.
Firebrick pursues development of Nasodine for use in children
Firebrick Pharma is pleased to announce that the Paediatric Investigation Plan (PIP) for Nasodine Nasal Spray has been filed with the European Medicines Agency (EMA) Paediatric Committee (PDCO), in preparation for filing for marketing approval of Nasodine in Europe later this year. A Paediatric Investigation Plan or ‘PIP’ is a development plan aimed at ensuring…